# A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

> **NCT04535544** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 52 (actual)

## Conditions studied

- Hepatitis D, Chronic

## Interventions

- **DRUG:** JNJ-73763989
- **DRUG:** Placebo
- **DRUG:** Entecavir (ETV) monohydrate
- **DRUG:** Tenofovir disoproxil
- **DRUG:** Tenofovir alafenamide (TAF)

## Key facts

- **NCT ID:** NCT04535544
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-17
- **Primary completion:** 2023-10-19
- **Final completion:** 2025-03-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04535544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04535544, "A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04535544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*